Personal Wealth Partners Purchases Shares of 1,241 Merck & Co., Inc. (NYSE:MRK)

Personal Wealth Partners purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,241 shares of the company’s stock, valued at approximately $104,000.

Other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Merck & Co., Inc. by 5.6% during the fourth quarter. BlackRock Inc. now owns 194,589,541 shares of the company’s stock valued at $14,868,587,000 after buying an additional 10,315,510 shares during the last quarter. Geode Capital Management LLC raised its position in Merck & Co., Inc. by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 34,032,366 shares of the company’s stock worth $2,596,161,000 after purchasing an additional 3,219,877 shares in the last quarter. Northern Trust Corp raised its position in Merck & Co., Inc. by 3.0% in the fourth quarter. Northern Trust Corp now owns 32,497,759 shares of the company’s stock worth $2,483,154,000 after purchasing an additional 951,911 shares in the last quarter. Norges Bank acquired a new position in Merck & Co., Inc. in the fourth quarter worth about $2,166,688,000. Finally, Jennison Associates LLC raised its position in Merck & Co., Inc. by 323.1% in the fourth quarter. Jennison Associates LLC now owns 15,777,286 shares of the company’s stock worth $1,205,542,000 after purchasing an additional 12,048,406 shares in the last quarter. Institutional investors own 75.16% of the company’s stock.

Merck & Co., Inc. stock traded up $0.79 during trading hours on Friday, hitting $85.52. 8,149,935 shares of the stock were exchanged, compared to its average volume of 10,057,636. The company has a quick ratio of 1.06, a current ratio of 1.21 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $216.94 billion, a PE ratio of 19.71, a P/E/G ratio of 1.72 and a beta of 0.56. Merck & Co., Inc. has a 12 month low of $65.68 and a 12 month high of $87.07. The stock has a 50-day moving average of $83.31.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.14. The firm had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $10.94 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.06 earnings per share. As a group, sell-side analysts expect that Merck & Co., Inc. will post 4.91 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, September 13th. This represents a $2.20 annualized dividend and a yield of 2.57%. Merck & Co., Inc.’s dividend payout ratio is 50.69%.

Several research analysts recently issued reports on the stock. UBS Group increased their price target on shares of Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Mizuho reissued a “buy” rating and issued a $97.00 price target on shares of Merck & Co., Inc. in a research report on Monday, August 5th. Citigroup increased their price target on shares of Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. They noted that the move was a valuation call. Credit Suisse Group reissued a “buy” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday. Finally, Argus increased their price target on shares of Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $91.07.

In other Merck & Co., Inc. news, CFO Robert M. Davis sold 216,718 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total transaction of $18,514,218.74. Following the sale, the chief financial officer now directly owns 354,378 shares of the company’s stock, valued at $30,274,512.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.27% of the stock is currently owned by corporate insiders.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: What is the QQQ ETF?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.